Rghei Amira D, Stevens Brenna A Y, Thomas Sylvia P, Yates Jacob G E, McLeod Benjamin M, Karimi Khalil, Susta Leonardo, Bridle Byram W, Wootton Sarah K
Department of Pathobiology, University of Guelph.
Department of Pathobiology, University of Guelph;
J Vis Exp. 2021 Jun 30(172). doi: 10.3791/62727.
Adeno-associated virus (AAV) vectors are among the most clinically advanced gene therapy vectors, with three AAV gene therapies approved for humans. Clinical advancement of novel applications for AAV involves transitioning from small animal models, such as mice, to larger animal models, including dogs, sheep, and nonhuman primates. One of the limitations of administering AAV to larger animals is the requirement for large quantities of high-titer virus. While suspension cell culture is a scalable method for AAV vector production, few research labs have the equipment (e.g., bioreactors) or know how to produce AAV in this manner. Moreover, AAV titers are often significantly lower when produced in suspension HEK 293 cells as compared to adherent HEK293 cells. Described here is a method for producing large quantities of high-titer AAV using cell stacks. A detailed protocol for titering AAV as well as methods for validating vector purity are also described. Finally, representative results of AAV-mediated transgene expression in a sheep model are presented. This optimized protocol for large-scale production of AAV vectors in adherent cells will enable molecular biology laboratories to advance the testing of their novel AAV therapies in larger animal models.
腺相关病毒(AAV)载体是临床上最先进的基因治疗载体之一,已有三种AAV基因疗法获批用于人类。AAV新应用的临床推进涉及从小动物模型(如小鼠)过渡到更大的动物模型,包括狗、绵羊和非人灵长类动物。将AAV施用于更大动物的局限性之一是需要大量高滴度病毒。虽然悬浮细胞培养是生产AAV载体的一种可扩展方法,但很少有研究实验室拥有相关设备(如生物反应器)或知道如何以这种方式生产AAV。此外,与贴壁HEK293细胞相比,在悬浮HEK 293细胞中生产时,AAV滴度通常显著更低。本文介绍了一种使用细胞堆叠生产大量高滴度AAV的方法。还描述了AAV滴度测定的详细方案以及验证载体纯度的方法。最后,展示了AAV介导的转基因在绵羊模型中表达的代表性结果。这种在贴壁细胞中大规模生产AAV载体的优化方案将使分子生物学实验室能够在更大动物模型中推进其新型AAV疗法的测试。